openPR Logo
Press release

U.S. Biosimilars Market Set For Rapid Growth Forecast 2020-2026| Key Players: F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co., Celltrion Inc., Coherus BioSciences, Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company

09-03-2021 08:27 AM CET | Health & Medicine

Press release from: Fortune Business Insights

U.S. Biosimilars Market Set For Rapid Growth Forecast

U.S. Biosimilars Market | 2021 Size, Growth, Share, Cap, Regional Analysis With Global Industry Forecast To 2027. The “U.S. Biosimilars Market” will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” The U.S. Biosimilars Market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market. As per the report, The U.S. Biosimilars Market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.

Key Players Operating in The U.S. Biosimilars Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

Hoffmann-La Roche Ltd.,
AbbVie Inc.,
Merck & Co.,
Celltrion Inc.,
Coherus BioSciences, Inc.,
Teva Pharmaceutical Industries Ltd.,
Eli Lilly and Company
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990

Increased Research and Development Initiatives to Drive the Market

Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.

Out research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers & acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.

The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others. In 2018, the autoimmune diseases held a market share of 92.0%. The segment is anticipated to remain in the leading position the U.S. biosimilars market during the forecast period. Factors like increasing adoption of biosimilars, rise in the prevalence of autoimmune diseases, and availability of limited drugs are likely to boost the segment. The Centers of Disease Control and Prevention declared that approximately 26% adults are estimated to have arthritis by 2040.

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market. Furthermore, the report offers a detailed analysis and information as per U.S. Biosimilars Market Growth Analysis by manufacturers, market segments helping our readers to get a comprehensive overview of the global market. Several players are planning to focus on developing cost-effective products or services, aiming to maintain a strong foothold in the market.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/u-s-biosimilars-market-100990

Detailed Table of Content:

Introduction
1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

Executive Summary
Market Dynamics
3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

Key Insights
4.1 Prevalence of Key Disease Associated with the Scope - U.S., 2018

4.2 New Product Launch

4.3 Pipeline Analysis

4.4 Regulatory Scenario

4.5. Reimbursement Scenario

4.6. Patent Snapshot of Biologics

4.6 Key Industry Developments - Partnerships, Mergers & Acquisitions

U.S. Biosimilars Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Drug Class

5.2.1 Filgrastim & Pegfilgrastim

5.2.2 Monoclonal Antibodies

5.2.2 Others

5.3. Market Analysis, Insights and Forecast – By Disease Indication

5.3.1 Cancer

5.3.2 Autoimmune Diseases

5.3.2.1 Arthritis

5.3.2.2 Psoriasis

5.3.2.3 Neutropenia

5.3.2.4 Others

5.3.3 Others

5.4. Market Analysis, Insights and Forecast – By Distribution Channel

5.4.1 Hospital Pharmacy

5.4.2 Retail Pharmacy

5.4.3 Online Pharmacy

Competitive Analysis
6.1. Key Industry Developments

6.2. U.S. Market Share Analysis (2018)

6.3. Competition Dashboard

6.4. Comparative Analysis – Major Players

6.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))

6.5.1 Novartis AG

6.5.2 Pfizer Inc.

6.5.3 Coherus BioSciences, Inc.

6.5.4 Teva Pharmaceutical Industries Ltd.

6.5.5 Merck & Co., Inc.

6.5.6 AbbVie Inc.

6.5.7 F. Hoffmann-La Roche Ltd.

6.5.8 Eli Lilly and Company

6.5.9 Celltrion Inc.

6.5.10 Amgen Inc.

6.5.11 Other Prominent Players

Strategic Recommendations
Continued...

Report Focus:

Extensive product offerings
Customer research services
Robust research methodology
Comprehensive reports
Latest technological developments
Value chain analysis
Potential U.S. Biosimilars Market opportunities
Growth dynamics
Quality assurance
Post-sales support
Regular report updates

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release U.S. Biosimilars Market Set For Rapid Growth Forecast 2020-2026| Key Players: F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co., Celltrion Inc., Coherus BioSciences, Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company here

News-ID: 2379620 • Views: 82

More Releases from Fortune Business Insights

Immunoglobulin Market to Reach USD 18,378.0 Million by 2025; FDA Approval for AD …
Market Overview: The global immunoglobulin market size is expected to reach USD 18,378.0 million by 2025 exhibiting a CAGR of 7.0% during the forecast period. The increasing diagnosis rates owing to escalating awareness regarding the treatment of immunoglobulins will have a tremendous effect on the market during the forecast period, states Fortune Business Insights in a report, titled “Immunoglobulin Market Size, Share and Industry Analysis By Route of Administration (Intravenous (IV),
Life Science Instrumentation 2021 Global Market Research report covers a detaile …
Global Life Science Instrumentation market2020 industry research report gives Advancement strategies and plans are talked about just as assembling procedures and cost structures are likewise examined. Life Science Instrumentation Market Report states import/send out utilization, organic market Figures, cost, value, income and gross edges. This report also studies the global Life Science Instrumentation market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels
Hospital Acquired Infections Treatment 2021 Global Market Research report covers …
Global Hospital Acquired Infections Treatment market2020 industry research report gives Advancement strategies and plans are talked about just as assembling procedures and cost structures are likewise examined. Hospital Acquired Infections Treatment Market Report states import/send out utilization, organic market Figures, cost, value, income and gross edges. This report also studies the global Hospital Acquired Infections Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and
Anti-Inflammatory Biologics Market 2021-2026 Study & Future Prospects Including …
Anti-Inflammatory Biologics Market | 2021 Global Industry Forecast To 2026, is latest report on Global Anti-Inflammatory Biologics Industry, published by Fortune Business Insights. Report provides comprehensive information on Global Anti-Inflammatory Biologics Market and Impact of Covid-19 on Healthcare Industry. According to report Global market value of Anti-Inflammatory Biologics is to hit USD 149.80 billion value by 2027 at CAGR of 11.0%. Report segments Anti-Inflammatory Biologics Market By Drug Class (Anti-Tumor

All 5 Releases


More Releases for Biosimilars

Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on